Results 181 to 190 of about 33,993 (277)

Continuous Support During Active Labor “The Heartbeat of Our Practice”: Swedish Midwives' Perspectives on Continuous Support During Active Labor

open access: yesBirth, EarlyView.
ABSTRACT Background Continuous intrapartum support is associated with improved childbirth experiences and clinical outcomes and is central to the WHO Labor Care Guide. Although related to practical support, “being with” a laboring woman is not identical to doing tasks; “being with” is described as a professional ideal and the cornerstone of woman ...
Louise Lundborg   +7 more
wiley   +1 more source

Genetic markers involved in neuroinflammation in Down syndrome: a systematic review. [PDF]

open access: yesDement Neuropsychol
Silva MN   +8 more
europepmc   +1 more source

Gold‐standard evidence and best practice guidance for menstrual cycle‐informed clinical care: An overview for clinicians

open access: yesBritish Journal of Clinical Psychology, EarlyView.
Abstract Objectives To synthesize current evidence and provide clinically actionable recommendations for integrating menstrual cycle‐related processes—particularly hormone sensitivity, Premenstrual Dysphoric Disorder (PMDD) and Premenstrual Exacerbation (PME)—into psychological assessment, formulation and treatment.
Ellen R. Lambert   +2 more
wiley   +1 more source

The Interfaces Twitter Elections Dataset: Construction process and characteristics of big social data during the 2022 presidential elections in Brazil. [PDF]

open access: yesPLoS One
Iasulaitis S   +6 more
europepmc   +1 more source

A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial

open access: yesBritish Journal of Haematology, EarlyView.
The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne   +28 more
wiley   +1 more source

Patient‐specific genomic measurable residual disease markers for monitoring acute myeloid leukaemia and myeloid malignancy

open access: yesBritish Journal of Haematology, EarlyView.
Standardised DNA based measurable residual disease (MRD) monitoring is possible for acute myeloid leukaemia (AML) and myeloid malignancy patients. Targeted next‐generation sequencing (NGS) and RNA‐seq permit marker development for clinically identified lesions and whole genome sequencing (WGS) permits MRD marker development in patients without ...
Libby Huang   +45 more
wiley   +1 more source

Home - About - Disclaimer - Privacy